# A Study on the Safety and Immune Response of AS37 Together With Hepatitis B Antigen in Adults Aged 18-45 Years

> **NCT05561673** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 122 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **COMBINATION_PRODUCT:** GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide
- **BIOLOGICAL:** GSK's HBsAg candidate vaccine adjuvanted with GSK's AS03 adjuvant system
- **BIOLOGICAL:** GSK's Hepatitis B vaccine adjuvanted with GSK's AS04 adjuvant system
- **BIOLOGICAL:** GSK's HBsAg (20 μg) vaccine adjuvanted with GSK's AS37B adjuvant system (50 μg)
- **BIOLOGICAL:** GSK's HBsAg (20 μg) vaccine adjuvanted with GSK's AS37A adjuvant system (100 μg)

## Key facts

- **NCT ID:** NCT05561673
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-04
- **Primary completion:** 2024-11-29
- **Final completion:** 2024-11-29
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2026-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05561673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05561673, "A Study on the Safety and Immune Response of AS37 Together With Hepatitis B Antigen in Adults Aged 18-45 Years". Retrieved via AI Analytics 2026-09-22 from https://api.ai-analytics.org/clinical/NCT05561673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*